Analyst Reco. 2seventy bio, Inc.

Equities

TSVT

US9013841070

Real-time Estimate Cboe BZX Other stock markets 01:54:54 2024-04-26 pm EDT			5-day change	1st Jan Change
4.235 ^USD	-1.28%		-6.64%	-1.17%

Apr. 19	US FDA mandates label updates on CAR-T cancer therapies	RE
Apr. 05	Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Leerink Upgrades 2seventy bio to Outperform From Market Perform, Raises Price Target to $18 From $5	Jan. 31	MT
TD Cowen Downgrades 2seventy bio to Market Perform From Outperform	Jan. 31	MT
Wedbush Raises 2seventy bio's PT to $5 From $2 After Announced Sale of Research, Development Projects to Regeneron, Keeps Neutral Rating	Jan. 30	MT
Wedbush Downgrades 2seventy bio to Neutral From Outperform, Does Not See Clear Catalyst for Shares Near Term; Lowers PT to $2 From $4	Nov. 20	MT
Wedbush Adjusts 2seventy bio Price Target to $4 From $7, Maintains Outperform Rating	Nov. 14	MT
Wedbush Adjusts 2seventy bio Price Target to $7 From $11, Maintains Outperform Rating	23-10-26	MT
Citigroup Initiates 2seventy bio at Buy Rating With $13 Price Target	23-10-12	MT
Guggenheim Downgrades 2seventy bio to Neutral From Buy	23-09-13	MT
Goldman Sachs Downgrades 2seventy bio to Neutral From Buy With $5 Price Target	23-09-13	MT
Wedbush Lowers 2seventy bio's Price Target to $11 From $22, Keeps Outperform Rating	23-09-12	MT
Guggenheim Adjusts Price Target on 2seventy bio to $26 From $27, Maintains Buy Rating	23-08-15	MT
Goldman Sachs Cuts Price Target on 2seventy bio to $24 From $27, Maintains Buy Rating	23-08-15	MT
Morgan Stanley Downgrades 2seventy bio to Equalweight From Overweight, Adjusts Price Target to $13 From $25	23-07-28	MT
Wedbush Lowers 2seventy bio's PT to $22 From $26, Removes DARIC33 From Valuation, Adjusts ABECMA Sales Ramp; Keeps Outperform Rating	23-07-28	MT
Morgan Stanley Adjusts Price Target on 2seventy bio to $25 From $28, Maintains Overweight Rating	23-07-20	MT
Wedbush Raises 2seventy bio's Price Target to $26 From $24, Adjusts ABECMA Profit/Loss Assumptions; Keeps Outperform Rating	23-05-04	MT
Wedbush Raises 2seventy bio's PT to $24 From $21, Updates Model to Include Adjustments to ABECMA Sales Ramp; Keeps Outperform Rating	23-04-27	MT
Wedbush Lowers 2seventy bio's Price Target to $21 From $28, Keeps Outperform Rating	23-03-17	MT
Wedbush Raises 2seventy bio's Price Target to $30 From $28, Keeps Outperform Rating	23-02-03	MT
Morgan Stanley Trims Price Target on 2seventy bio to $28 From $29, Maintains Overweight Rating	23-01-24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. 2seventy bio, Inc.

Equities

TSVT

US9013841070

Analyst Reco.

Filters